Founded in 2017, Hims & Hers Health, Inc. has developed a digital-first, subscription-based telehealth platform that offers treatment for chronic conditions across sexual health, dermatology, mental health, and more. The company’s growth has accelerated, turning profitable in recent years despite regulatory headwinds and investments in AI-driven preventive care and acquisitions. Significant capex and stock buybacks reflect strategic reinvestment and shareholder return priorities. However, the evolving regulatory environment around compounded pharmaceuticals and telehealth practices presents ongoing risks that could influence future growth trajectories. Close attention to customer acquisition efficacy and regulatory developments will be key milestones.